ATE312088T1 - Säureempfindliche verbindungen, deren herstellung und verwendungen - Google Patents

Säureempfindliche verbindungen, deren herstellung und verwendungen

Info

Publication number
ATE312088T1
ATE312088T1 AT01967418T AT01967418T ATE312088T1 AT E312088 T1 ATE312088 T1 AT E312088T1 AT 01967418 T AT01967418 T AT 01967418T AT 01967418 T AT01967418 T AT 01967418T AT E312088 T1 ATE312088 T1 AT E312088T1
Authority
AT
Austria
Prior art keywords
acid
compounds
acidic
production
biologically active
Prior art date
Application number
AT01967418T
Other languages
English (en)
Inventor
Michel Bessodes
Christophe Masson
Daniel Scherman
Barbara Wetzer
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0011278A external-priority patent/FR2813605B1/fr
Application filed by Centelion filed Critical Centelion
Application granted granted Critical
Publication of ATE312088T1 publication Critical patent/ATE312088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Polyethers (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
AT01967418T 2000-09-05 2001-09-03 Säureempfindliche verbindungen, deren herstellung und verwendungen ATE312088T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0011278A FR2813605B1 (fr) 2000-09-05 2000-09-05 Composes acidosensibles, leur preparation et utilisations
US23911600P 2000-10-11 2000-10-11
PCT/FR2001/002725 WO2002020510A1 (fr) 2000-09-05 2001-09-03 Composes acidosensibles, leur preparation et utilisations

Publications (1)

Publication Number Publication Date
ATE312088T1 true ATE312088T1 (de) 2005-12-15

Family

ID=26212598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01967418T ATE312088T1 (de) 2000-09-05 2001-09-03 Säureempfindliche verbindungen, deren herstellung und verwendungen

Country Status (13)

Country Link
US (1) US20050085426A1 (de)
EP (1) EP1317439B1 (de)
JP (1) JP2004508364A (de)
KR (1) KR20030040441A (de)
CN (1) CN1452617A (de)
AT (1) ATE312088T1 (de)
AU (1) AU2001287801A1 (de)
CA (1) CA2421179A1 (de)
DE (1) DE60115667T2 (de)
HU (1) HUP0303379A3 (de)
IL (1) IL154736A0 (de)
MX (1) MXPA03001876A (de)
WO (1) WO2002020510A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633774B1 (de) 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Makrozyklische motilin rezeptorantagonisten
FR2925491B1 (fr) * 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
KR101014246B1 (ko) 2008-07-03 2011-02-16 포항공과대학교 산학협력단 페하 민감성 금속 나노 입자 및 이의 제조 방법.
GB201307438D0 (en) * 2013-04-25 2013-06-05 Airbus Uk Ltd Fuel Additive
KR101725240B1 (ko) 2015-03-24 2017-04-11 부산대학교 산학협력단 UV-광 반응성 및 pH 반응성을 갖는 이중 자극 반응성 코어-쉘 자성나노입자 및 이를 포함하는 약물 전달체
EP3095790A1 (de) 2015-05-22 2016-11-23 Universite De Bordeaux Nukleosidlipidverbindungen mit ph-empfindlichen dialkylorthoesterketten und deren verwendung zum transport oder zur vektorisierung von mindestens einem therapeutischen wirkstoff
WO2019165442A1 (en) * 2018-02-26 2019-08-29 Waters Technologies Corporation Acid labile surfactants and method for performing protein solubilization or enzyme digestion
CN116656706B (zh) * 2023-04-18 2024-08-20 河南中医药大学第一附属医院 一种酸敏融合蛋白重组质粒及其构建、应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4406686A (en) * 1981-07-24 1983-09-27 Stauffer Chemical Company Haloalkylaminomethyldioxolane herbicide antidotes
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations

Also Published As

Publication number Publication date
DE60115667T2 (de) 2006-08-24
HUP0303379A3 (en) 2004-03-01
EP1317439A1 (de) 2003-06-11
KR20030040441A (ko) 2003-05-22
AU2001287801A1 (en) 2002-03-22
JP2004508364A (ja) 2004-03-18
CA2421179A1 (en) 2002-03-14
DE60115667D1 (de) 2006-01-12
HUP0303379A2 (hu) 2004-01-28
EP1317439B1 (de) 2005-12-07
WO2002020510A1 (fr) 2002-03-14
CN1452617A (zh) 2003-10-29
IL154736A0 (en) 2003-10-31
MXPA03001876A (es) 2004-09-10
US20050085426A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Wang et al. Metal-organic frameworks for stimuli-responsive drug delivery
Cai et al. Metal–organic framework‐based stimuli‐responsive systems for drug delivery
Xie et al. O2-Cu/ZIF-8@ Ce6/ZIF-8@ F127 composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy
Bahrani et al. Zinc-based metal–organic frameworks as nontoxic and biodegradable platforms for biomedical applications: review study
Rojas et al. Metal organic frameworks based on bioactive components
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
RU2008112146A (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
BRPI0608291A2 (pt) agente imunossupressor e agente antitumoral que compreendem composto heterocìclico como ingrediente ativo
CN103563983A (zh) 一种纳米银过氧化物复合杀菌液及其制备方法
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
HK1064295A1 (en) Medical aerosol formulations
Dua et al. Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives
ATE312088T1 (de) Säureempfindliche verbindungen, deren herstellung und verwendungen
ECSP066663A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
CN104306984A (zh) 水溶性硅量子点作为药物载体的应用
Zhao et al. Nanoscale metal− organic frameworks and their nanomedicine applications
ATE438385T1 (de) Pharmazeutische zusammensetzung
Liao et al. Functionally modified halloysite nanotubes for personalized bioapplications
ES2855985T3 (es) Agente terapéutico para su uso en el tratamiento de infecciones
CN101797387A (zh) 一种可携带基因和药物的磁性靶向载体及其制备方法和应用
Gao et al. Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy
Liu et al. A pH-responsive supramolecular drug delivery system constructed by cationic pillar [5] arene for enhancing antitumor activity
Nematollahi et al. Covalent organic frameworks and metal-organic frameworks against pathogenic viruses and antibiotic-resistant bacteria: Diagnostic and therapeutic applications

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties